Positioning

AbbVie in position to become largest pharma by 2028, narrowly edging out Roche — report – Endpoints News

future-dyanmics

Thanks to the success of its Covid-19 vaccine Comirnaty, Pfizer currently holds the top spot in Evaluate Pharma’s ranking of pharma companies by sales — but not for long, according to analysts.
A new Evaluate Pharma report predicts that Pfizer will drop down four spots by 2028, with AbbVie pegged to become the top-selling pharma with an estimated $65.7 billion in sales.
Despite approaching a fast-approaching patent cliff for Humira, AbbVie has candidates in the pipeline to replace that lost revenue, such as Skyrizi, Rinvoq and Venclexta, according to analysts. CEO Rick Gonzalez picked up on that note earlier this year when he predicted Skyrizi and Rinvoq will become Humira’s successors, taking up all of its indications plus atopic dermatitis.
Unlock this story instantly and join 143,100+ biopharma pros reading Endpoints daily — and it’s free.
Gilead has raided one of the up-and-coming cell therapy 2.0 biotechs to find its new head of pharma development and manufacturing.
Dan O’Day’s pharma player has recruited Stacey Ma from Sana Biotechnology for the senior executive team. A Genentech vet, Ma has been head of technical operations at Sana, which has just opted to change up its manufacturing building plans in favor of Seattle over their original site in California. Sana CEO Steve Harr had proudly held Ma up as one of the top R&D execs at the company.
Unlock this story instantly and join 143,100+ biopharma pros reading Endpoints daily — and it’s free.
Sanofi CEO Paul Hudson made clear earlier this year that his mission to reshape the company would involve some pipeline pruning. For the right price that apparently includes Libtayo, mere months ahead of an expected FDA decision on lung cancer.
Regeneron is putting down a whopping $900 million upfront for the full rights to Libtayo, their partnered PD-1 treatment that earned Regeneron $306 million last year, up 13% from the year before.
Roche has signed a $1.3 billion deal to gain worldwide rights to an experimental cancer drug chief dealmaker James Sabry believes can play a big role in fighting multiple cancers.
The pharma giant is putting up $125 million of that in an upfront, along with $55 million in near-term rewards for a big piece of the potential action on camonsertib (RP-3500), an oral small molecule inhibitor of ATR, or Ataxia-Telangiectasia and Rad3-related protein kinase, in development at Repare Therapeutics $RPTX.
Unlock this story instantly and join 143,100+ biopharma pros reading Endpoints daily — and it’s free.
In the latest development over alleged patent infringement related to Pfizer’s and Moderna’s mRNA vaccines for Covid-19, Pfizer is stepping up to the plate and sharing its side of the story.
RNAi therapeutics giant Alnylam knew before it filed its original suit that Pfizer’s Covid vaccine Comirnaty did not violate Alnylam’s patent, Pfizer wrote in its 37-page response filed late last week in Delaware district court in response to Alnylam’s suit. Alnylam had alleged patent infringement and demanded monetary compensation.
Unlock this story instantly and join 143,100+ biopharma pros reading Endpoints daily — and it’s free.
Months after a slate of pharma companies slammed the brakes on some operations in both Russia and Ukraine, Novartis announced that it’s resuming business remotely in Ukraine “to help the war-torn country restore some basic critical business processes.”
Novartis came to the decision after studying safety protocols and receiving advice “which we will regularly review,” the company said on Wednesday.
As the regular flow of NDA and BLA submissions continues to pick up, it’s little wonder that an already Covid-beleaguered FDA seems to be increasingly turning to refuse-to-file letters as a means to provide instructive feedback, and perhaps even to slow the pace of its workload.
The latest RTF letter, disclosed Thursday by Aeglea BioTherapeutics, a penny-stock, clinical-stage biotech company calls for new efficacy data to be included in its BLA for pegzilarginase for the treatment of the rare, progressive and debilitating disease characterized by high levels of arginine, and known as Arginase 1 Deficiency. The company’s stock price fell by more than 40% on Thursday.
Some companies celebrate anniversaries with cake and a party. Women’s health pharma Organon is celebrating its 1-year spinoff from Merck by introducing a series of vibrant murals at different global facilities and putting an environmental, social and governance (ESG) stake in the ground.
The fledgling company — although with many established products and teams developed under Merck — is sharing images of 9 murals created by local women artists near its manufacturing, research and now corporate headquarters. Each of the paintings is unique, but unite under the theme “Her Promise, Our Purpose” to help draw attention to women’s health inequities.
Unlock this story instantly and join 143,100+ biopharma pros reading Endpoints daily — and it’s free.
The Institute for Clinical and Economic Review, a drug pricing watchdog, gave a measured thumbs up on Thursday morning to bluebird’s potentially expensive new gene therapy for a rare but debilitating blood disorder, which will go before an FDA advisory committee next Friday.
While bluebird raised some sticker-shock eyebrows with its proposed price of $2.1 million per treatment course of what’s known as beti-cel, ICER said previously in April and again today that the therapy would be cost-effective, as long as there’s an 80% payback option for patients who do not achieve and maintain transfusion independence over a five-year period.
In a rare move, a long-time veteran of the FDA’s pharma quality and compliance team is moving over to an India-based generic drugmaker with a history of noncompliance.
Diana Amador-Toro, who spent almost four decades with FDA including stints as a program director for the office of pharmaceutical quality operations, was hired in April by Indian generic drug manufacturer Lupin as the company’s senior vice president of global compliance, where she will be handling the company’s compliance function including training, internal audits and investigations.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source

future-dyanmics

Related posts
Positioning

Shielding of actin by the endoplasmic reticulum impacts nuclear positioning - Nature.com

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To…
Read more
Positioning

9th Abu Dhabi Strategic Debate: the value of the UAE's ambiguous position - Atalayar

Wednesday, December 7 , 2022PUBLICIDAD PHOTO/PAVEL BEDNYAKOK via REUTERS …
Read more
Positioning

Continued top-line growth and strong solvency position - Zurich Insurance

“The Group continues to be on track to exceed its strategic and financial targets for the…
Read more
Newsletter
Join THE PRO PEOPLE Family

Sign up for The Pro People Community's Daily Digest and get the best of Industry updates, tailored for you.

Leave a Reply

Your email address will not be published. Required fields are marked *